The Medical Letter website uses cookies. By continuing to browse this website you are agreeing to our use of cookies. Find out more      
The Medical Letter on Drugs and Therapeutics
Ertugliflozin for Type 2 Diabetes
The full article is available to subscribers Subscriber Login   

The FDA has approved the sodium-glucose co-transporter 2 (SGLT2) inhibitor ertugliflozin (Merck) for treatment of adults with type 2 diabetes, both alone (Steglatro) and in fixed-dose combinations with metformin (Segluromet) and sitagliptin (Steglujan). Ertugliflozin is the fourth SGLT2 inhibitor to be approved in the US. All four are available in combination with metformin and three are available in combination with a dipeptidyl peptidase-4 (DPP-4) inhibitor (see Table 3).

SGLT2 INHIBITORS — SGLT2 inhibitors decrease renal glucose reabsorption and increase urinary glucose excretion, reducing fasting and postprandial blood glucose levels. When used as monotherapy or in addition to other drugs, they reduce A1C by 0.5-1%. SGLT2 inhibitors also reduce systolic blood pressure by 3-6 mm Hg and have been associated with an average weight loss of 0.1-4 kg. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Ertugliflozin for Type 2 Diabetes
Article code: 1545c
 Electronic, downloadable article - $25